Drug
Aclidinium Bromide
Aclidinium Bromide: highest development phase Post-Market, developed by AstraZeneca. 1 trial record tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- AstraZeneca
Trials
| Drug | Phase | Indication |
|---|---|---|
| Aclidinium Bromide NCT02375724 | Post-Market | Pulmonary Disease, Chronic Obstructive |
Latest
No recent events.
Follow Aclidinium Bromide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.